PDS Biotechnology (PDSB) News Today $1.24 -0.04 (-3.13%) Closing price 04:00 PM EasternExtended Trading$1.23 -0.01 (-0.73%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PDSB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period PDS Biotechnology announces data from its VERSATILE-002 Phase 2 trialAugust 25 at 1:44 PM | msn.comPDS Biotechnology Announces Promising Phase 2 Trial ResultsAugust 25 at 1:44 PM | msn.comPDS Biotechnology stock rises after announcing promising cancer trial dataAugust 25 at 1:44 PM | za.investing.comPDS Biotechnology Reports 39.3-Month Median Overall Survival in VERSATILE-002 Trial for HPV16-Positive Head and Neck CancerAugust 25 at 9:10 AM | quiverquant.comQPDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck CancerAugust 25 at 8:30 AM | globenewswire.comQ3 EPS Forecast for PDS Biotechnology Boosted by AnalystAugust 17, 2025 | marketbeat.comPDS Biotechnology (NASDAQ:PDSB) Announces Quarterly Earnings ResultsAugust 15, 2025 | marketbeat.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | insidermonkey.comPDS Biotechnology Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comPDS Biotechnology reports Q2 EPS (21c), consensus (23c)August 13, 2025 | msn.comPDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs UpdateAugust 13, 2025 | globenewswire.comInsights into PDS Biotechnology's Upcoming EarningsAugust 12, 2025 | benzinga.comPDS Biotechnology (PDSB) Projected to Post Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comPDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comPDS Biotechnology (NASDAQ:PDSB) Trading 8.7% Higher - What's Next?July 24, 2025 | marketbeat.comPDS Biotechnology stock rises after trial meets criteria for expansionJuly 10, 2025 | investing.comPDS Biotechnology Shares Climb Following Trial Expansion MilestoneJuly 10, 2025 | msn.comPDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 ResultsJuly 10, 2025 | globenewswire.comPDS Biotechnology (NASDAQ:PDSB) Given "Buy" Rating at HC WainwrightJuly 1, 2025 | marketbeat.comPDS Biotechnology Corporation (PDSB) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comPDS Biotechnology (NASDAQ:PDSB) Stock Rating Lowered by Wall Street ZenJune 14, 2025 | marketbeat.comHC Wainwright Expects Reduced Earnings for PDS BiotechnologyJune 13, 2025 | marketbeat.comPDS Biotechnology (NASDAQ:PDSB) Receives "Buy" Rating from HC WainwrightJune 11, 2025 | marketbeat.comPDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCCJune 9, 2025 | globenewswire.comPDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society ...June 3, 2025 | morningstar.comMPDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingJune 2, 2025 | globenewswire.comPDS Biotechnology files to sell 9.82M shares of common stock for holdersMay 28, 2025 | msn.comWall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to "Hold"May 26, 2025 | marketbeat.comQ2 EPS Estimates for PDS Biotechnology Increased by B. RileyMay 24, 2025 | marketbeat.comPDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of ...May 23, 2025 | uk.finance.yahoo.comPDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingMay 22, 2025 | globenewswire.comPDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company ShowcaseMay 20, 2025 | globenewswire.comEarnings call transcript: PDS Biotech’s Q1 2025 results show reduced lossesMay 16, 2025 | uk.investing.comPDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...May 15, 2025 | finance.yahoo.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comPDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comPDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate UpdateMay 14, 2025 | globenewswire.comInsights Ahead: PDS Biotechnology's Quarterly EarningsMay 14, 2025 | benzinga.comPDS Biotechnology (PDSB) to Release Earnings on WednesdayMay 11, 2025 | marketbeat.comPDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 9, 2025 | globenewswire.comPDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual MeetingMay 8, 2025 | globenewswire.comPDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial ResultsMay 7, 2025 | globenewswire.comPDS Biotechnology price target lowered to $5 from $7 at B. RileyApril 26, 2025 | markets.businessinsider.comB. Riley Predicts Stronger Earnings for PDS BiotechnologyApril 26, 2025 | marketbeat.comPDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2025 | globenewswire.comPDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual MeetingApril 16, 2025 | globenewswire.comPDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025April 8, 2025 | globenewswire.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comAlliance Global Partners Remains a Buy on PDS Biotechnology (PDSB)March 29, 2025 | markets.businessinsider.com Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PDSB Media Mentions By Week PDSB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PDSB News Sentiment▼0.551.03▲Average Medical News Sentiment PDSB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PDSB Articles This Week▼62▲PDSB Articles Average Week Get the Latest News and Ratings for PDSB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for PDS Biotechnology and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ENGN News Today GNFT News Today CRGX News Today ACIU News Today HRTX News Today OGI News Today AARD News Today IPHA News Today LYEL News Today CGTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PDSB) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access